Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)
Johnson & Johnson (JNJ) posted Construction in Progress of $4.3 billion for Q1 2021, up 18.67% sequentially from $3.6 billion in Q4 2019, and up 18.67% YoY from $3.6 billion in Q1 2020.
Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021) Analysis & Trends
Johnson & Johnson (JNJ) has 10 years of Construction in Progress data on file, last reported at $4.3 billion in Q1 2021.
- Quarterly Construction in Progress rose 18.67% year-over-year to $4.3 billion in Q1 2021, while the trailing twelve-month figure through Jan 2021 was $4.3 billion (up 18.67% YoY) and the FY2021 annual result came in at $4.3 billion, up 18.67% from the prior year.
- Construction in Progress improved to $4.3 billion in Q1 2021 per JNJ's latest filing, from $3.6 billion in the prior quarter.
- The five-year high for Construction in Progress was $4.3 billion in Q1 2021, with the low at $3.4 billion in Q1 2017.
- Average Construction in Progress over 4 years is $3.7 billion, with a median of $3.6 billion recorded in 2019.
- Year-over-year, Construction in Progress retreated 6.17% in 2019 and grew 18.67% in 2021.
- Johnson & Johnson's Construction in Progress stood at $3.4 billion in 2017, then grew by 12.41% to $3.9 billion in 2018, then dropped by 6.17% to $3.6 billion in 2019, then increased by 18.67% to $4.3 billion in 2021.
- Business Quant data shows JNJ's Construction in Progress at $4.3 billion in Q1 2021, $3.6 billion in Q4 2019, and $3.9 billion in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 3, 2021 | 4.32 Bn |
| Dec 29, 2019 | 3.64 Bn |
| Dec 30, 2018 | 3.88 Bn |
| Dec 31, 2017 | 3.45 Bn |
| Jan 1, 2017 | 3.35 Bn |
| Jan 3, 2016 | 3.53 Bn |
| Dec 28, 2014 | 3.60 Bn |
| Dec 29, 2013 | 3.30 Bn |
| Dec 30, 2012 | 2.74 Bn |
| Jan 1, 2012 | 2.50 Bn |
| Jan 2, 2011 | 2.58 Bn |
| Jan 3, 2010 | 2.52 Bn |